RegeneRx Biopharmaceuticals, Inc. (RGRX)
OTCMKTS
· Delayed Price · Currency is USD
0.0014
0.00 (0.00%)
Jan 21, 2025, 3:00 PM EST
RGRX Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | Upgrade
|
| Revenue Growth (YoY) | -0.00% | 0% | 0% | -0.00% | 10.18% | 22.97% | Upgrade
|
| Cost of Revenue | - | - | 0.01 | 0 | 0.07 | 0.08 | Upgrade
|
| Gross Profit | 0.08 | 0.08 | 0.07 | 0.07 | 0.01 | -0.01 | Upgrade
|
| Selling, General & Admin | 1.44 | 1.48 | 1.4 | 1.37 | 1.27 | 1.31 | Upgrade
|
| Operating Expenses | 1.44 | 1.48 | 1.4 | 1.37 | 1.27 | 1.31 | Upgrade
|
| Operating Income | -1.36 | -1.4 | -1.33 | -1.29 | -1.26 | -1.32 | Upgrade
|
| Interest Expense | -0.33 | -0.33 | -0.32 | -0.23 | -0.15 | -0.09 | Upgrade
|
| Interest & Investment Income | 0 | 0 | 0 | 0 | 0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.58 | Upgrade
|
| EBT Excluding Unusual Items | -1.69 | -1.73 | -1.65 | -1.52 | -1.4 | -1.99 | Upgrade
|
| Other Unusual Items | - | - | 0.06 | - | - | - | Upgrade
|
| Pretax Income | -1.69 | -1.73 | -1.6 | -1.52 | -1.4 | -1.99 | Upgrade
|
| Net Income | -1.69 | -1.73 | -1.6 | -1.52 | -1.4 | -1.99 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.08 | - | Upgrade
|
| Net Income to Common | -1.69 | -1.73 | -1.6 | -1.52 | -1.49 | -1.99 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 1.74% | 3.58% | 3.93% | 1.82% | 8.49% | -0.18% | Upgrade
|
| EPS (Basic) | -1.18 | -1.20 | -1.15 | -1.14 | -1.14 | -1.65 | Upgrade
|
| EPS (Diluted) | -1.18 | -1.20 | -1.15 | -1.14 | -1.14 | -2.00 | Upgrade
|
| Free Cash Flow | -0.82 | -0.94 | -0.99 | -1.01 | -1.14 | -0.89 | Upgrade
|
| Free Cash Flow Per Share | -0.57 | -0.66 | -0.71 | -0.76 | -0.87 | -0.74 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 91.35% | 93.59% | 15.18% | -16.33% | Upgrade
|
| Operating Margin | -1775.75% | -1826.44% | -1730.71% | -1686.46% | -1643.89% | -1899.56% | Upgrade
|
| Profit Margin | -2199.83% | -2250.43% | -2081.47% | -1984.56% | -1936.91% | -2861.55% | Upgrade
|
| Free Cash Flow Margin | -1073.15% | -1225.52% | -1290.10% | -1311.77% | -1482.47% | -1275.06% | Upgrade
|
| EBITDA | - | - | - | -1.29 | -1.26 | -1.32 | Upgrade
|
| D&A For EBITDA | - | - | - | 0 | 0 | 0 | Upgrade
|
| EBIT | -1.36 | -1.4 | -1.33 | -1.29 | -1.26 | -1.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.